EP1003473A1 - Composition and method for treatment of aging skin - Google Patents

Composition and method for treatment of aging skin

Info

Publication number
EP1003473A1
EP1003473A1 EP99919884A EP99919884A EP1003473A1 EP 1003473 A1 EP1003473 A1 EP 1003473A1 EP 99919884 A EP99919884 A EP 99919884A EP 99919884 A EP99919884 A EP 99919884A EP 1003473 A1 EP1003473 A1 EP 1003473A1
Authority
EP
European Patent Office
Prior art keywords
skin
composition
cells
effective amount
adp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99919884A
Other languages
German (de)
French (fr)
Inventor
Thomas Mammone
Donald F. Collins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Color Access Inc
Original Assignee
Color Access Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Color Access Inc filed Critical Color Access Inc
Publication of EP1003473A1 publication Critical patent/EP1003473A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the invention relates to cosmetic and pharmaceutical compositions.
  • the invention relates to cosmetic and pharmaceutical compositions which enhance skin cell energy and rejuvenate aging skin cells.
  • the present invention now provides a means for enhancing the ATP levels of aged fibroblasts.
  • the invention provides a method for increasing ATP levels in aging cells which comprises applying to the skin an effective amount of ADP, AMP, or oxaloacetic acid, or a combination thereof.
  • the method is particularly useful in increasing energy in skin cells, particularly fibroblasts.
  • the invention also provides cosmetic and pharmaceutical compositions for topical application to the skin comprising effective amounts of ADP, AMP, or oxaloacetate, or a combination thereof in a cosmetically or pharmaceutically acceptable carrier.
  • the terms "ADP", "AMP” and "oxaloacetic acid” shall include safe and effective derivatives thereof which retain qualitatively the same activity.
  • the present invention is based on an observation that the extrinsic provision of ADP, AMP or oxaloacetic acid (oxaloacetate) to skin cells results in an increase of cell energy present in the cells so treated.
  • ADP, AMP or oxaloacetic acid is provided to normal fibroblasts in culture, ATP levels can be increased substantially.
  • use of ADP and/or AMP and/or oxaloacetic acid as active agents in the treatment and prevention of skin aging is indicated.
  • compositions of the invention comprise effective amounts of ADP, AMP or a combination thereof, in combination with a cosmetically or pharmaceutically acceptable carrier.
  • effective amount is meant that amount of the active agent which can increase the amount of ATP in a treated cell at least about 10%, preferably at least about 20%, more preferably at least about 30%, and most preferably at least about 40%, relative to untreated cells.
  • concentration of the active agent will be from about 0.001-10%, preferably about 0.01-5%, by weight of the total composition; the concentration may be varied depending upon the intended frequency of use of the composition, lower concentrations being employed with more frequent applications.
  • the active components can be formulated with a variety of cosmetically and/or pharmaceutically acceptable carriers.
  • pharmaceutically or cosmetically acceptable carrier refers to a vehicle, for either pharmaceutical or cosmetic use, which vehicle delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms.
  • pharmaceutical or cosmetic will be understood to encompass both human and animal pharmaceuticals or cosmetics.
  • Useful carriers include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1, 3-diol, isopropyl myristate, isopropyl palmitate, or mineral oil.
  • the carrier may be in any form appropriate to the mode of delivery, for example, solutions, colloidal dispersions, emulsions (oil-in-water or water-in- oil) , suspensions, creams, lotions, gels, foams, mousses, sprays and the like.
  • the active agents of the invention can be used alone to increase the energy level of skin cells generally, so as to delay or reverse the onset of the cellular symptoms of aging.
  • aging as used in the present specification and claims, is meant both photoaging, i.e., the premature aging which occurs as the result of excessive exposure to UV rays, and chronological aging, i.e., the naturally occurring, normal aging of the skin which occurs over time, even without prolonged sun exposure.
  • the compositions of the invention are particularly suited for enhancing the energy levels of fibroblasts and keratinocytes in both normal and aging skin. Increase in energy levels of fibroblasts can be expected to delay or reverse the decrease in collagen and elastin production that characterizes aged fibroblasts.
  • the increase in energy levels of keratinocytes can be expected to result in a delay in the thinning of the epidermis observed in aging skin.
  • the use of the active agents of the invention is not limited to skin cells, however, but may also be expected to aid in energy increase in, for example, aging muscle or other connective tissue cells.
  • Treatment of aging skin, or prevention of aging in normal, non-aged skin is preferably achieved by regular application of the composition over a period of time.
  • a preferred method of obtaining the benefits of the composition is via chronic topical application of a safe and effective amount of a composition containing the mixture, to prevent or delay development of skin damage which may result from photo- or chronoaging, or to prevent worsening of or to reverse already established damage.
  • topical application of the composition in an amount of from about 0.1 ⁇ g/cm 2 to 2 mg/cm 2 of exposed skin, be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day.
  • chromenic application it is meant herein that the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about six months to about ten years, more preferably still from about one year to about five years, thereby resulting in the treatment or prevention of the external signs of photoaging and chronological aging.
  • the compositions of the invention may also be used on a less frequent basis, for example, once or twice a month, as a sort of "spa treatment" with a higher level of active component provided on these occasions.
  • the actives of the invention can also be combined with other anti-aging or skin-enhancing agents.
  • the actives of the invention can be combined, for example, with one or more of the following products: alpha- or beta- hydroxy acids, such as lactic acid, glycolic acid, citric acid, alpha-hydroxyoctanoic acid, alpha-hydroxydecanoic acid, alpha-hydroxylauric acid, tartaric acid, glucouronic acid, galactouronic acid, alpha-hydroxybutyric acid, alpha- hydroxyisobutyric acid, malic acid, mandelic acid, pyruvic acid, and tartronic acid, and salicylic acid; retinoids, such as retinol, retinyl acetate, retinyl palmitate, retinyl butyrate, retinyl oleate, retinyl linoleate, and retinoic acid; and DHEA and derivatives thereof.
  • alpha- or beta- hydroxy acids
  • the formulation in addition to the carrier and active agents, also can comprise other components which may be chosen depending on the carrier and/or the intended use of the formulation. Additional components include, but are not limited to, water soluble colorants (such as FD&C Blue #1) ; oil soluble colorants (such as D&C Green #6) ; water soluble sunscreens (such as Eusolex 232) ; oil soluble sunscreens (such as octyl methoxycinnamate) ; particulate sunscreens (such as zinc oxide) ; antioxidants (such as BHT) ; chelating agents (such as disodium EDTA) ; emulsion stabilizers (such as carbomer) ; preservatives (such as methyl paraben) ; fragrances (such as pinene) ; flavoring agents (such as sorbitol) ; humectants (such as glycerine) ; waterproofing agents (such as PVP/Eicosene Copolymer) ; water soluble film
  • compositions can be therapeutic products, ADP and/or AMP and/or oxaloacetic acid being the sole actives, or in combination with other actives.
  • the compositions can also be a makeup products, for example, a lipstick, foundation, concealer, bronzer, blush, eyeshadow and the like.
  • Normal human dermal fibroblasts are grown to confluence in flasks, and then divided into three different treatment sets. Testing is done at the point at which the cells have undergone 32 population doublings. The treatments are with ADP (Sigma), AMP(Yamasa Shoyu Co., Inc.), and creatine monophosphate (Sigma) , each at five different concentrations ranging from 0.01-1.0 mM. The growth medium serves as a control.
  • the cells are treated for a period of 2 hours, and then trypsinized, washed and resuspended to 6X10 6 cells/ml.
  • the cells are treated with a releasing agent, sodium lauryl sulfate, which causes the ATP contained within the cells to be released.
  • the releasate is then added to a solution containing luciferin and luciferase.
  • Luciferase utilizes the energy provided by free ATP to convert luciferin to oxyluciferin.
  • the light released by this reaction is read on a spectrophotometer; the amount produced is proportional to the amount of ATP available.
  • the ATP levels are calculated from an ATP standard curve, and then normalized on a per cell basis. The results are shown in Table 1. TABLE 1
  • This example illustrates the increase in cell energy levels produced by treatment of cells with oxaloacetic acid.
  • Normal human dermal fibroblasts are grown to subconfluence in flasks, treated with oxaloacetic acid for two hours with three samples, having concentrations of 0.05 mM, 0.50mM and 1.0 mM. The cells are then trypsinized, washed and resuspended to 6X10 6 cells/ml. The treated cells have undergone four passages. The cells are further treated and analyzed as described in the previous example, with the amount of ATP calculated at the various dosages. The results are shown in Table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a topical composition for application to the skin comprising an effective amount of ADP, AMP or oxaloacetic acid, or a combination thereof, with a cosmetically or pharmaceutically acceptable carrier. The compositions of the invention can be used to increase the energy level of cells, particularly skin cells, and to treat and prevent the symptoms of aging in the skin.

Description

COMPOSITION AND METHOD FOR TREATMENT OF AGING SKIN
Field of the Invention
The invention relates to cosmetic and pharmaceutical compositions. In particular, the invention relates to cosmetic and pharmaceutical compositions which enhance skin cell energy and rejuvenate aging skin cells.
Background of the Invention
As anyone into their middle years recognizes, the skin undergoes a number of mostly undesirable changes as it ages. These nature of these changes has now been fairly well documented on gross, tissue, and cellular levels. It is all too readily apparent to the naked eye that the skin of older individuals is drier, has more lines and wrinkles, and is generally more slack or loose than it was in youth. On the tissue level, many of these gross changes can be attributed to alterations in the production of collagen, which is greatly reduced in quantity, as well as being wasted and degraded in appearance. Interestingly, age-related changes can also be detected at the cellular and molecular level. As fibroblasts age, their cellular functions begin to decline. In particular, it has been observed that aging human fibroblasts in vi tro are less responsive to stimuli which induce migration of cells in culture, and also replicate less frequently. Muggleton-Harris and Aroian, Soπtat. Cell Genet. 8_: 41-50, 1982. It has been suggested that these changes are somehow related to age-related deficiencies in the normal cycle of ATP utilization and restoration. However, studies on the loss of replication have been said to indicate that it is not related to deficiencies in the ATP-restoring pathways (Goldstein et al. J. Cell Phys. 112: 419-424, 1982). Muggleton-Harris and DeFuriadn Vitro Cell. Devel. Biol. 21.: 271-276, 1985) in treating cells with metabolic poisons, showed that there is an age-dependent change in cells' ATP content and turnover rate, leading to the suggestion that aging cells lose some of their capacity to utilize ATP. Whatever the reason, however, the end result is an apparently inevitable reduced production in collagen, resulting in the typical skin atrophy seen in aged skin, and this loss of cellular function and decline in cell appearance appear to inextricably intertwined.
It would be desirable to be able to alter this inexorable descent into cellular old age, in the hopes of prolonging the "youthful" energy exhibited by younger fibroblast cells. However, to date, there has been no remedy for this aspect of the aging of skin cells. The present invention now provides a means for enhancing the ATP levels of aged fibroblasts. Summary of the Invention
The invention provides a method for increasing ATP levels in aging cells which comprises applying to the skin an effective amount of ADP, AMP, or oxaloacetic acid, or a combination thereof. The method is particularly useful in increasing energy in skin cells, particularly fibroblasts. The invention also provides cosmetic and pharmaceutical compositions for topical application to the skin comprising effective amounts of ADP, AMP, or oxaloacetate, or a combination thereof in a cosmetically or pharmaceutically acceptable carrier.. As used herein, the terms "ADP", "AMP" and "oxaloacetic acid" shall include safe and effective derivatives thereof which retain qualitatively the same activity.
Detailed Description of the Invention The present invention is based on an observation that the extrinsic provision of ADP, AMP or oxaloacetic acid (oxaloacetate) to skin cells results in an increase of cell energy present in the cells so treated. In particular, when ADP, AMP or oxaloacetic acid is provided to normal fibroblasts in culture, ATP levels can be increased substantially. Thus, use of ADP and/or AMP and/or oxaloacetic acid as active agents in the treatment and prevention of skin aging is indicated.
The compositions of the invention comprise effective amounts of ADP, AMP or a combination thereof, in combination with a cosmetically or pharmaceutically acceptable carrier. By "effective amount" is meant that amount of the active agent which can increase the amount of ATP in a treated cell at least about 10%, preferably at least about 20%, more preferably at least about 30%, and most preferably at least about 40%, relative to untreated cells. In a typical composition, the concentration of the active agent will be from about 0.001-10%, preferably about 0.01-5%, by weight of the total composition; the concentration may be varied depending upon the intended frequency of use of the composition, lower concentrations being employed with more frequent applications.
For topical application, the active components) can be formulated with a variety of cosmetically and/or pharmaceutically acceptable carriers. The term "pharmaceutically or cosmetically acceptable carrier" refers to a vehicle, for either pharmaceutical or cosmetic use, which vehicle delivers the active components to the intended target and which will not cause harm to humans or other recipient organisms. As used herein, "pharmaceutical" or "cosmetic" will be understood to encompass both human and animal pharmaceuticals or cosmetics. Useful carriers include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1, 3-diol, isopropyl myristate, isopropyl palmitate, or mineral oil. Methodology and components for formulation of cosmetic and pharmaceutical compositions are well known, and can be found, for example, in Remington's Pharmaceutical Sciences, Eighteenth Edition, A.R. Gennaro, Ed., Mack Publishing Co. Easton Pennsylvania, 1990. The carrier may be in any form appropriate to the mode of delivery, for example, solutions, colloidal dispersions, emulsions (oil-in-water or water-in- oil) , suspensions, creams, lotions, gels, foams, mousses, sprays and the like.
The active agents of the invention can be used alone to increase the energy level of skin cells generally, so as to delay or reverse the onset of the cellular symptoms of aging. By "aging", as used in the present specification and claims, is meant both photoaging, i.e., the premature aging which occurs as the result of excessive exposure to UV rays, and chronological aging, i.e., the naturally occurring, normal aging of the skin which occurs over time, even without prolonged sun exposure. The compositions of the invention are particularly suited for enhancing the energy levels of fibroblasts and keratinocytes in both normal and aging skin. Increase in energy levels of fibroblasts can be expected to delay or reverse the decrease in collagen and elastin production that characterizes aged fibroblasts. Similarly, the increase in energy levels of keratinocytes can be expected to result in a delay in the thinning of the epidermis observed in aging skin. The use of the active agents of the invention is not limited to skin cells, however, but may also be expected to aid in energy increase in, for example, aging muscle or other connective tissue cells. Treatment of aging skin, or prevention of aging in normal, non-aged skin is preferably achieved by regular application of the composition over a period of time. A preferred method of obtaining the benefits of the composition is via chronic topical application of a safe and effective amount of a composition containing the mixture, to prevent or delay development of skin damage which may result from photo- or chronoaging, or to prevent worsening of or to reverse already established damage. It is suggested as an example that topical application of the composition, in an amount of from about 0.1 μg/cm2 to 2 mg/cm2 of exposed skin, be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day. By "chronic" application, it is meant herein that the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about six months to about ten years, more preferably still from about one year to about five years, thereby resulting in the treatment or prevention of the external signs of photoaging and chronological aging. However, the compositions of the invention may also be used on a less frequent basis, for example, once or twice a month, as a sort of "spa treatment" with a higher level of active component provided on these occasions.
The external signs of aging that the composition may alleviate include, but are not limited to, fine and deep lines and wrinkles, skin atrophy, reduction in skin thickness, changes in skin pigmentation, and reduction in hair growth.
In their function as general anti-aging agents, the actives of the invention can also be combined with other anti-aging or skin-enhancing agents. For this purpose, the actives of the invention can be combined, for example, with one or more of the following products: alpha- or beta- hydroxy acids, such as lactic acid, glycolic acid, citric acid, alpha-hydroxyoctanoic acid, alpha-hydroxydecanoic acid, alpha-hydroxylauric acid, tartaric acid, glucouronic acid, galactouronic acid, alpha-hydroxybutyric acid, alpha- hydroxyisobutyric acid, malic acid, mandelic acid, pyruvic acid, and tartronic acid, and salicylic acid; retinoids, such as retinol, retinyl acetate, retinyl palmitate, retinyl butyrate, retinyl oleate, retinyl linoleate, and retinoic acid; and DHEA and derivatives thereof.
The formulation, in addition to the carrier and active agents, also can comprise other components which may be chosen depending on the carrier and/or the intended use of the formulation. Additional components include, but are not limited to, water soluble colorants (such as FD&C Blue #1) ; oil soluble colorants (such as D&C Green #6) ; water soluble sunscreens (such as Eusolex 232) ; oil soluble sunscreens (such as octyl methoxycinnamate) ; particulate sunscreens (such as zinc oxide) ; antioxidants (such as BHT) ; chelating agents (such as disodium EDTA) ; emulsion stabilizers (such as carbomer) ; preservatives (such as methyl paraben) ; fragrances (such as pinene) ; flavoring agents (such as sorbitol) ; humectants (such as glycerine) ; waterproofing agents (such as PVP/Eicosene Copolymer) ; water soluble film-formers (such as hydroxypropyl methylcellulose) ; oil-soluble film formers (such as Hydrogenated C-9 Resin) ; cationic polymers (such as Polyquaternium 10) ; anionic polymers (such as xanthan gum) ; vitamins (such as tocopherol) ; and the like. As will be apparent, the compositions can be therapeutic products, ADP and/or AMP and/or oxaloacetic acid being the sole actives, or in combination with other actives. However, the compositions can also be a makeup products, for example, a lipstick, foundation, concealer, bronzer, blush, eyeshadow and the like.
The invention is further illustrated by the following non-limiting examples.
EXAMPLES Example I .
This example illustrates the increase in cell energy levels produced by treatment of cells with ADP or AMP.
Normal human dermal fibroblasts are grown to confluence in flasks, and then divided into three different treatment sets. Testing is done at the point at which the cells have undergone 32 population doublings. The treatments are with ADP (Sigma), AMP(Yamasa Shoyu Co., Inc.), and creatine monophosphate (Sigma) , each at five different concentrations ranging from 0.01-1.0 mM. The growth medium serves as a control.
The cells are treated for a period of 2 hours, and then trypsinized, washed and resuspended to 6X106 cells/ml. The cells are treated with a releasing agent, sodium lauryl sulfate, which causes the ATP contained within the cells to be released. The releasate is then added to a solution containing luciferin and luciferase. Luciferase utilizes the energy provided by free ATP to convert luciferin to oxyluciferin. The light released by this reaction is read on a spectrophotometer; the amount produced is proportional to the amount of ATP available. The ATP levels are calculated from an ATP standard curve, and then normalized on a per cell basis. The results are shown in Table 1. TABLE 1
Sample ATP(pg/cell) % increase
Media control 14.7
ADP O.OlmM 14.0 -5 0.05mM 17.7 20 O.lOmM 18.7 27 0.50mM 23.0 56 l.OOmM 20.7 41
AMP O.OlmM 14.7 0 0.05mM 19.0 29 O.lOmM 19.0 29 0.50mM 20.0 36 l.OOmM 19.3 31
Creatine O.OlmM 16.7 14 0.05mM 13.3 -9 O.lOmM 14.7 0 0.50mM 12.7 -14 l.OOmM 15.0 2
The results shown above indicate that ADP increases ATP levels in fibroblasts in a dose dependent manner. AMP is also found to increase the ATP levels of treated cells, but not to the same extent as ADP, and not in a dose dependent manner. Creatine monophosphate, however, does not significantly increase ATP levels at any dose tested. The maximal increase achieved by ADP is +56% at 0.5mM, whereas the maximal increase achieved by AMP is +36% at 0.5mM. Example 2
This example illustrates the increase in cell energy levels produced by treatment of cells with oxaloacetic acid.
Normal human dermal fibroblasts are grown to subconfluence in flasks, treated with oxaloacetic acid for two hours with three samples, having concentrations of 0.05 mM, 0.50mM and 1.0 mM. The cells are then trypsinized, washed and resuspended to 6X106 cells/ml. The treated cells have undergone four passages. The cells are further treated and analyzed as described in the previous example, with the amount of ATP calculated at the various dosages. The results are shown in Table 2.
TABLE 2
Sample ATP (pg/cell) % increase
Media control 1.67
OxAc 0.05mM 1.92 15
0.50mM 2.58 55 l.OmM 2.17 30
These data show that oxaloacetic acid at all concentrations increased ATP levels in treated cells, with a maximal increase of 55% observed at the O.lmM dose.

Claims

What we claim is :
1. A cosmetic or pharmaceutical composition for topical application to the skin comprising an effective amount of ADP, AMP or oxaloacetic acid, or a combination thereof, with a cosmetically or pharmaceutically acceptable carrier.
2. The composition of claim 1 comprising from about 0.001 to about 10% of ADP, AMP, oxaloacetic acid or a combination thereof.
3. The composition of claim 2 comprising from about 0.1 to about 5% of ADP, AMP, oxaloacetic acid or a combination thereof.
4. The composition of claim 1 comprising ADP.
5. The composition of claim 1 comprising AMP.
6. The composition of claim 1 comprising oxaloacetic acid.
7. A method for increasing the energy level in cells which comprises applying to the skin an effective amount of the composition of claim 1.
8. The method of claim 7 in which the cells are skin cells.
9. The method of claim 8 in which the cells are fibroblasts.
10. A method for increasing the energy level in skin cells which comprises applying to the skin an effective amount of the composition of claim 2.
10
11. A method for increasing the energy level in skin cells which comprises applying to the skin an effective amount of the composition of claim 3.
12. A method for increasing the energy level in skin cells which comprises applying to the skin an effective amount of the composition of claim 4.
13. A method for increasing the energy level in skin cells which comprises applying to the skin an effective amount of the composition of claim 5.
14. A method for increasing the energy level in skin cells which comprises applying to the skin an effective amount of the composition of claim 6.
15. A method of treating or preventing symptoms of aging in the skin which comprises applying to the skin an effective amount of the composition of claim 1.
16. The method of claim 15 in which the symptom is skin atrophy.
17. The method of claim 15 in which the symptom is loss of skin thickness.
18. The method of claim 15 in which the symptoms are lines and wrinkles.
11
EP99919884A 1998-04-27 1999-04-22 Composition and method for treatment of aging skin Ceased EP1003473A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67059 1987-06-25
US6705998A 1998-04-27 1998-04-27
PCT/US1999/008497 WO1999055302A1 (en) 1998-04-27 1999-04-22 Composition and method for treatment of aging skin

Publications (1)

Publication Number Publication Date
EP1003473A1 true EP1003473A1 (en) 2000-05-31

Family

ID=22073462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99919884A Ceased EP1003473A1 (en) 1998-04-27 1999-04-22 Composition and method for treatment of aging skin

Country Status (6)

Country Link
EP (1) EP1003473A1 (en)
JP (1) JP2001503447A (en)
KR (1) KR100426753B1 (en)
AU (1) AU744295B2 (en)
CA (1) CA2294482C (en)
WO (1) WO1999055302A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
EP1512405B1 (en) 2002-05-20 2013-08-14 Otsuka Pharmaceutical Co., Ltd. Composition comprising adenosine monophosphate for treating melasma
JP4129574B2 (en) 2002-08-06 2008-08-06 大塚製薬株式会社 Anti-aging agent
JP5093998B2 (en) * 2004-09-22 2012-12-12 大塚製薬株式会社 Pigmentation preventing or improving agent
WO2006066244A2 (en) * 2004-12-17 2006-06-22 Cash Alan B Method for extending lifespan and delaying the onset of age-related disease
KR101283303B1 (en) * 2007-01-31 2013-07-12 (주)아모레퍼시픽 Composition for external use containing stable α-keto acids obtained by controlling pH of the composition, and method for stabilizing the α-keto acids
JP2009298752A (en) * 2008-06-17 2009-12-24 Shiseido Co Ltd Skin care preparation composition for external use
JP2012530683A (en) * 2009-06-19 2012-12-06 大塚製薬株式会社 Preventive or therapeutic agent for abnormal skin water permeability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4702913A (en) * 1983-12-28 1987-10-27 Roussel Uclaf Novel cosmetic compositions
US5256649A (en) * 1989-05-23 1993-10-26 Elf Sanofi Cosmetic composition against aging of the skin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844103B2 (en) * 1990-02-09 1999-01-06 株式会社コーセー External preparation for skin
JP3413220B2 (en) * 1992-08-17 2003-06-03 株式会社コーセー Skin roughness improver
JP3172599B2 (en) * 1992-10-16 2001-06-04 株式会社コーセー Cell activator
JPH0899860A (en) * 1994-09-30 1996-04-16 Kose Corp Skin external agent
JP3578858B2 (en) * 1995-12-11 2004-10-20 株式会社ノエビア Skin preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4702913A (en) * 1983-12-28 1987-10-27 Roussel Uclaf Novel cosmetic compositions
US5256649A (en) * 1989-05-23 1993-10-26 Elf Sanofi Cosmetic composition against aging of the skin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9955302A1 *

Also Published As

Publication number Publication date
AU744295B2 (en) 2002-02-21
CA2294482A1 (en) 1999-11-04
JP2001503447A (en) 2001-03-13
CA2294482C (en) 2007-01-16
KR100426753B1 (en) 2004-04-13
AU3750499A (en) 1999-11-16
KR20010014120A (en) 2001-02-26
WO1999055302A1 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
US6337320B1 (en) Reparatives for ultraviolet radiation skin damage
AU639063B2 (en) Skin care compositions
US9974984B2 (en) Combination of monosaccharides with antioxidants and use thereof
US20060204458A1 (en) Anti-aging methods and composition
CA2397198C (en) Echinacea extract as anti-irritant and anti-aging booster in cosmetic compositions
JPH1087476A (en) Boraginaceae seed oil as irritation inhibitor in composition containing hydroxy acid or retinoid
US20020044913A1 (en) Cosmetics to support skin metabolism
US20050186158A1 (en) Use of creatine or creatine compounds for skin preservation
KR100590141B1 (en) Cosmetic Composition
WO2002015860A1 (en) Topical antioxidant having vitamin c and method of combination with topical agent by user
JP2002504504A (en) Anti-irritant in cosmetic compositions
KR19990087346A (en) New topical compositions
US20120065261A1 (en) Creatine compositions for skin treatment
JP2001002559A (en) Turmeric acting as anti-inflammatory agent in composition containing hydroxy acid or retinoid
BRPI0905400A2 (en) cosmetic use of a make-up, make-up and device
WO2002011717A9 (en) Cosmetics to support skin metabolism
CA2294482C (en) Treatment of aging skin
US6630442B1 (en) Reparatives for chemosurgery and laser (thermal) therapy
JPH11505818A (en) Cosmetic or dermatological preparations containing phytic acid
CA2590119A1 (en) Anti-aging methods and composition
JP2002370962A (en) Bleaching preparation and cosmetic for preventing and improving aging of skin
KR20000041499A (en) Cosmetic base composition containing stabilized l-ascorbic acid
Riccardi Reversal of photoaging of the skin by topical d-alpha tocopherol, ascorbic acid, and L-selenomethionine: A comparative analysis performed by light and transmission electron microscopy
BRPI0905229B1 (en) COSMETIC USE OF A COMPOSITION, COSMETIC COMPOSITION, DEVICE, AND, JOINT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20000504

17Q First examination report despatched

Effective date: 20021015

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20050107